<img src="https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7?size=2" nborder="0" align="left" hspace="5" vspace="5" title="22157.jpg" alt="Company Logo"/>One-Year Analytical Tool Delivers Near-Real-Time Pipeline Alerts on 319 Targets/Antigens/Armor and 1,200+ Funding Rounds as GlaxoSmithKline, BioNTech, and Inovio Lead a Field That Saw 76 New Vaccines in 2024/25 AloneDublin, Sept. 07, 2026 <a href="https://www.globenewswire.com" target="_blank">(GLOBE NEWSWIRE)</a> -- The <a href="https://www.researchandmarkets.com/reports/6113726/unlocking-opportunity-dominate-the-cancer?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=9sjx9j&amp;utm_campaign=2345156+-+Unlocking+Opportunity%3a+Dominate+the+Cancer+Vaccine+Market+with+Confidence+Now+Available.+Tracks+960%2b+Organizations+and+2%2c100%2b+Drugs+Across+the+Full+Cancer+Vaccine+Pipeline&amp;utm_exec=clshmsai" rel="nofollow" target="_blank" title="Unlocking Opportunity: Dominate the Cancer Vaccine Market with Confidence">"Unlocking Opportunity: Dominate the Cancer Vaccine Market with Confidence"</a> has been added to ResearchAndMarkets.com's offering. Cancer Vaccines Analytical Tool Advances Oncology Pipeline Intelligence and Strategic Decision-Making The Cancer Vaccines Analytical Tool provides comprehensive, continuously updated intelligence for organizations navigating the rapidly evolving cancer vaccine market. Designed for oncology drug developers, biotechnology companies, pharmaceutical organizations, investors, academic institutions, and business development teams, the platform combines competitive intelligence, clinical trial analytics, licensing data, and pipeline tracking in one web-based resource. During 2024 and 2025, the oncology pipeline recorded 76 new cancer vaccines, more than 300 drugs associated with key events, and 1,946 events across 1,412 drug programs. This accelerating activity highlights the need for reliable, near-real-time intelligence to identify emerging technologies, evaluate competitors, monitor clinical progress, and uncover strategic opportunities. Comprehensive Cancer Vaccine Market Intelligence The Cancer Vaccines Analytical Tool tracks innovation across personalized neoantigen vaccines, armored vaccine technologies, mRNA platforms, combination immunotherapies, artificial intelligence, multi-omics, and next-generation sequencing. These developments are supporting increasingly precise therapeutic strategies, stronger immune responses, scalable development, and sustained antitumor activity. Users can apply the platform's oncology intelligence to: <ul><li>Monitor active organizations, cancer vaccine developers, drug candidates, targets, antigens, technologies, and tumor types.</li><li>Evaluate licensing and partnership opportunities through access to biotechnology developers, academic projects, historical deals, and business development contacts.</li><li>Create data-driven reports and presentations using exportable graphs, tables, and near-real-time market intelligence.</li><li>Identify key opinion leaders and clinical or scientific experts influencing cancer vaccine research and development.</li><li>Assess oncology-focused investors and funding activity across the global market.</li><li>Analyze developments presented at major oncology conferences, including AACR, ASCO, ESMO, and ASH.</li></ul> Continuous platform updates and monthly email alerts help users remain informed about new drugs, clinical trials, targets, companies, deals, biomarkers, and other significant developments. Unlike static market reports, the tool includes a full year of online access, new features, pipeline alerts, training resources, and dedicated support. Advanced Oncology Clinical and Competitive Intelligence Powered by an award-winning, AI-enhanced intelligence platform with more than 25 years of oncology expertise, the Cancer Vaccines Analytical Tool supports decisions throughout oncology drug development. Its global coverage spans start-ups, established biotechnology companies, pharmaceutical organizations, academic institutions, technologies, targets, and commercial opportunities. The platform includes licensing contacts, a worldwide investor network, historical deal information, and academic-commercial projects. Clinical development intelligence covers more than 3,000 biomarkers, including stratifying, predictive, and pharmacodynamic markers, as well as companion diagnostic programs from early development through approval. Clinical trial coverage extends beyond primary endpoints to include dosage, resistance mechanisms, adverse events, food effects, trial phase and status, first-in-human studies, tumor stage and grade, and line of therapy. Combination therapy analytics also organize targets, modalities, indications, and development stages, enabling users to assess evolving oncology treatment strategies efficiently. Real-world evidence and multi-point analytics can be segmented by development stage, drug modality, co-medication profile, or biomarker cluster. These capabilities support contextual analysis and evidence-based decisions across cancer vaccine research, clinical development, business development, licensing, and investment. Coverage at a Glance <ul><li>More than 960 organizations monitored, including 798 corporate organizations, 461 private companies, 282 public companies, 102 academic institutions, 49 start-ups, 43 cancer centers or hospitals, and 34 large pharmaceutical or biotechnology companies.</li><li>More than 2,100 drugs, including over 160 discovery-stage and 630 preclinical programs.</li><li>More than 200 Phase 1, 300 Phase 2, and 73 Phase 3 programs.</li><li>Three pre-registration programs and 21 marketed products.</li><li>319 targets, antigens, or armor technologies across 144 tumor types.</li><li>1,053 clinical trials and 293 clinical biomarkers.</li><li>233 drugs assessed in combination therapy programs.</li><li>168 deals recorded during the past five years.</li><li>More than 2,000 business development and licensing contacts.</li><li>41 worldwide academic-commercial opportunity projects.</li><li>More than 1,200 funding activities during the past five years and 158 leading investors.</li></ul> Leading cancer vaccine developers tracked by the platform include OncoTherapy Science, Inovio, BioNTech, Theravectys, and GlaxoSmithKline. The most active nations represented include the United States, China, the United Kingdom, France, and Germany. Flexible Access and Ongoing Support The Cancer Vaccines Analytical Tool is a web-based application compatible with major modern browsers, including Chrome, Firefox, and Safari. Internet access is required. Users also receive 24/7 support, how-to training videos, practical case studies, and guidance for competitive pipeline analysis and business development. Organizations seeking broader oncology intelligence can renew access or upgrade to 1stOncology, a full-service platform supporting oncology research, clinical development, competitive analysis, licensing, partnerships, and strategic decision-making. Companies Featured <ul><li>BioNTech</li><li>GlaxoSmithKline</li><li>Inovio</li><li>OncoTherapy Science</li><li>Theravectys</li></ul> For more information about this directory visit <a href="https://www.researchandmarkets.com/reports/6113726/unlocking-opportunity-dominate-the-cancer?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=9sjx9j&amp;utm_campaign=2345156+-+Unlocking+Opportunity%3a+Dominate+the+Cancer+Vaccine+Market+with+Confidence+Now+Available.+Tracks+960%2b+Organizations+and+2%2c100%2b+Drugs+Across+the+Full+Cancer+Vaccine+Pipeline&amp;utm_exec=clshmsai" rel="nofollow" target="_blank" title="">https://www.researchandmarkets.com/r/reu5qd</a> About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. <pre>CONTACT: 
CONTACT: ResearchAndMarkets.com 
 Laura Wood,Senior Press Manager 
 press@researchandmarkets.com
 For E.S.T Office Hours Call 1-917-300-0470 
 For U.S./ CAN Toll Free Call 1-800-526-8630 
 For GMT Office Hours Call +353-1-416-8900 

</pre> <img alt="" src='https://ml.globenewswire.com/media/NDAzNmFhZmUtZWVkNi00OTYxLWIzZTktMTQ3NTU3NjdkNGFkLTEwMjY3MzctMjAyNi0wOS0wNy1lbg==/tiny/Research-and-Markets.png' referrerpolicy='no-referrer-when-downgrade' />

Unlocking Opportunity: Dominate the Cancer Vaccine Market with Confidence Now Available. Tracks 960+ Organizations and 2,100+ Drugs Across the Full Cancer Vaccine Pipeline

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn